Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
Nirav Dhanesha, Assistant Professor at the Louisiana State University, shared on LinkedIn:
”Latest publication from our lab in Blood Advance, Blood Journals Portfolio
Beyond its common application as a lineage marker to identify monocytes in flow-cytometry assays, CD14 is highly expressed in neutrophils and serves as a functional driver of DVT.
In this study, we identifies neutrophil CD14 as a specific driver and therapeutic target for DVT.
CoreFindings:
Identification: Multiomic profiling (RNA-seq, proteomics, flow cytometry) reveals neutrophil CD14 overexpression within 3-hr of DVT onset.
Mechanism: Elevated plasma G-CSF drives this CD14 expression via the transcription factor C/EBPα.
InVivo Validation: Neutrophil-specific CD14 knockdown significantly reduces DVT severity.
Translational Relevance: In G-CSF-stimulated primary human neutrophils, CD14 inhibition reduces inflammation and NETosis.
These data establish the G-CSF/C/EBPα/CD14 axis as a primary mechanism in DVT pathogenesis and suggest CD14 as a viable site for therapeutic intervention.
Link of the paper.
Congratulations to the first authors, Nilesh Pandey and Harpreet Kaur, Ph.D., for their hard work and persistence.
Many thanks to all the collaborators and co-authors for their contributions to this work.”
Article: Neutrophil CD14 is a Driver and a Therapeutic Target for Deep Vein Thrombosis
Authors: Nilesh Pandey, Harpreet Kaur, Raktim Mitra, Lakshmi Chandaluri, Nirvana Shaaban, Alexa Martinez, Evan Kidder, Sumit Kumar Anand, Megan Butler, Xiaolu Zhang, Dweipayan Goswami, Louise Frausto, Dhananjay Kumar, Rajan Pandit, Sandeep Das, Sumati Rohilla, Suman Mohajan, Gurranna Male, Amdadul Huque, Amr R Salem, Tarek Magdy, David S Gross, Karen Y Stokes, A Wayne Orr, Sultan Tousif, Arif Yurdagul Jr, Oren Rom, Nirav Dhanesha
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis
-
Jan 22, 2026, 10:16Mohamed Rawy Gives Clinical Tips for Management of Atrial Fibrillation